Repositioning Candidate Details

Candidate ID: R1303
Source ID: DB09351
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Levobetaxolol
Synonyms: (S)-betaxolol
Molecular Formula: C18H29NO3
SMILES: CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1
Structure:
DrugBank Description: Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
CAS Number: 93221-48-8
Molecular Weight: 307.434
DrugBank Indication: Used in the treatment of open-angle glaucoma and ocular hypertension .
DrugBank Pharmacology: Levobetaxolol is a selective β1 adrenergic receptor antagonist . It acts to lower intraocular pressure. Levobataxolol is condsidered to be the more active component of the betaxolol racemate.
DrugBank MoA: The exact mechanism by which levobetaxolol lowers intraocular pressure is not known. It it thought that antagonism of β-adrenergic receptors may reduce the production of aqueous humour stimulated via the cyclic adenosine monophosphate-protein kinase A pathway . It is also thought that the vasoconstriction produced by antagonism of β adrenergic receptors reduces blood flow to the eye and therefore the ultrafiltration responsible for aqueous humour production. β1 selective antagonists are less effective than non-selective β adrenergic receptor antagonists because β2 receptors make up the bulk of the population in the eye. They do, however, come with the benefit of reduced respiratory complications.
Targets: Beta-1 adrenergic receptor antagonist
Inclusion Criteria: Indication associated